| Dr Mikela Haldeman Yarawamai, MD | |
|
98-1079 Moanalua Rd Ste 600, Aiea, HI 96701-4716 | |
| (808) 485-3032 | |
| Not Available |
| Full Name | Dr Mikela Haldeman Yarawamai |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 98-1079 Moanalua Rd Ste 600, Aiea, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346516580 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 18016 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospice - Hawaii, Llc | Honolulu, HI | Hospice |
| Pali Momi Medical Center | Aiea, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Straub Clinic And Hospital | 6305759754 | 404 |
News Archive
Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies.
Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.
Researchers in the U.S. have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may alter key protein structures on red blood cells and compromise the transport and delivery of oxygen in patients with coronavirus disease 2019 (COVID-19).
› Verified 9 days ago
| Entity Name | Straub Clinic & Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306508 PECOS PAC ID: 6305759754 Enrollment ID: O20031111000417 |
News Archive
Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies.
Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.
Researchers in the U.S. have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may alter key protein structures on red blood cells and compromise the transport and delivery of oxygen in patients with coronavirus disease 2019 (COVID-19).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mikela Haldeman Yarawamai, MD 98-1079 Moanalua Rd Ste 600, Aiea, HI 96701-4716 Ph: (808) 485-3032 | Dr Mikela Haldeman Yarawamai, MD 98-1079 Moanalua Rd Ste 600, Aiea, HI 96701-4716 Ph: (808) 485-3032 |
News Archive
Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies.
Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.
Researchers in the U.S. have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may alter key protein structures on red blood cells and compromise the transport and delivery of oxygen in patients with coronavirus disease 2019 (COVID-19).
› Verified 9 days ago
Richard Kline, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 98-1079 Moanalua Rd, Aiea, HI 96701 Phone: 808-486-6000 | |
Kellie Wo, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 98-1005 Moanalua Rd Spc 3030, Aiea, HI 96701 Phone: 808-627-3254 | |
Samuel Andrade, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 98-1005 Moanalua Rd Spc 3030, Aiea, HI 96701 Phone: 808-627-3200 | |
David Lyn Swanson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 98-1079 Moanalua Rd, Aiea, HI 96701 Phone: 808-486-6000 | |
Dr. Agnes Serranilla-sonido, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 98-1005 Moanalua Rd Spc 3030, Aiea, HI 96701 Phone: 808-627-3254 Fax: 808-627-3265 | |
Dr. Thomas W. Spheeris, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 98-1079 Moanalua Rd, Aiea, HI 96701 Phone: 808-485-4250 | |
Dr. Michael Regal, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 99-1440 Aiea Heights Dr, #25, Aiea, HI 96701 Phone: 808-484-4561 |